Progenics undergoes restructuring, cuts 26% of workforce

Friday, September 21, 2012 02:15 PM

Progenics Pharmaceuticals, a Tarrytown, N.Y.-based biopharmaceutical company focused on cancer and related conditions, has announced companywide restructuring, including a reduction of its workforce. The company will continue to focus its resources and efforts on its oncology programs, particularly an upcoming phase II study of PSMA ADC in prostate cancer patients.

The restructuring actions include a reduction in annual cash expenditures by an estimated $8 million and a headcount reduction of 26%, with 77 employees remaining. The workforce reduction reflects termination of several early stage research projects, last year's out-licensing of Relistor to Salix Pharmaceuticals, and planned divestitures of the previously discontinued PRO 140 and C. difficile programs. Preclinical research will continue in the company's PI3K program and clinical development and manufacturing capabilities will be unaffected by the restructuring.

Furthermore, CFO Robert McKinney and senior vice president of quality Benedict Osorio are stepping down, effective September 30. Senior executive director and treasurer Angelo Lovallo will become principal financial officer and principal accounting officer.

"This restructuring reflects our commitment to strategic goals we announced a year ago, when we directed our resources toward addressing the growing need for novel and improved cancer therapies,” said Mark R. Baker, CEO of Progenics. “Our top clinical priority remains advancing PSMA ADC, while continuing to evaluate strategic in-licensing opportunities. While I believe this restructuring is the right next step in Progenics' ongoing efforts to benefit patients and shareholders, it is difficult to part with colleagues who have made significant contributions.”

Share:          
CWWeekly

March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs